Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here .
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. CME information and select publications here ....
Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD information and select publications here.
Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here .
Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here .
For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here ....
Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here .
Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. CME information and select publications here .
Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and select publications here .
Drs. Nooka and Richardson provide an update on multiple myeloma treatment, including recent ASCO highlights. They delve into antibody-drug conjugates (Belantamab Mafodotin), discuss the evolving role of oral cell modulators, and compare CAR-T therapies (Idacel, Siltacel) with bispecific antibodies (Teclistamab, Elranatamab, Talquetamab). The discussion covers clinical efficacy, real-world data, managing unique toxicities, and optimal sequencing in different patient scenarios.
Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here .
Leading lymphoma specialists discuss complex patient cases and clinical data shaping the care of Non-Hodgkin Lymphoma. The episode covers recent advances and strategies for diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, including updates on frontline regimens, BTK inhibitors, bispecific antibodies, and CAR T-cell therapy, addressing sequencing, toxicity management, and long-term care.
Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here .
Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here .
Dr. Patrick Wen discusses the evolution of glioma classification, highlighting the significance of IDH mutation status for prognosis and treatment. He details the development and FDA approval of vorasidenib for IDH-mutant gliomas, including its mechanism of action, clinical trial results, and ongoing debates regarding its optimal use. The episode also covers current management and innovative treatment strategies for glioblastoma, addressing challenges like the blood-brain barrier and the importance of specialized care.
This episode provides an in-depth review of significant developments in multiple myeloma management over the past year. Experts delve into emerging immunotherapies such as tri-specific antibodies, the re-evaluation of belantamab, and the evolving roles of anti-CD38 therapies in smoldering, induction, and maintenance settings. Discussions also cover the clinical utility of MRD testing, practical aspects of subcutaneous drug administration, and a strategic comparison of CAR-T and bispecific antibodies, including their associated toxicities and future applications.
Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here .
Drs. Stephen Ansell and Brian Hill review major treatment advances in non-Hodgkin lymphoma over the past year, focusing on diffuse large B-cell, mantle cell, and follicular lymphomas. The discussion covers new data on bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies, highlighting shifts in treatment paradigms, management of toxicities, and the role of MRD testing. They also explore emerging chemotherapy-free regimens and their impact on patient care.
This episode explores the latest advancements in treating systemic mastocytosis (SM) and myelofibrosis (MF). Clinical investigators delve into targeted therapies like avapritinib for SM, discussing its efficacy in both advanced and indolent forms, as well as managing side effects like brain fog. For MF, the discussion covers the four approved JAK inhibitors—ruxolitinib, fedratinib, pacritinib, and mamelotinib—addressing their benefits, challenges, and impact on patient quality of life. The episode also includes real-world patient cases, illustrating diagnostic complexities and treatment considerations for these rare hematologic conditions.
Clinical investigators discuss available data guiding the management of multiple myeloma. CME information and select publications here .
Dr. Rafael Fonseca provides an in-depth update on multiple myeloma from the ASH 2024 meeting. He shares practical insights on integrating bispecific antibodies and CAR-T therapies, discussing their efficacy, toxicity management, and optimal sequencing in different patient settings. The episode also explores the re-emergence of belantamab, the debate on treating smoldering myeloma, and the future of novel immunomodulators, offering a comprehensive overview of current and emerging treatment strategies.
Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here .
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here .
Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here .
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here .
Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma. CME information and select publications here .
Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here .
Dr Jennifer R Brown from Dana-Farber Cancer Institute in Boston and Prof Paolo Ghia from IRCCS Ospedale San Raffaele in Milano, Italy, summarize clinically relevant research findings and datasets over the past year regarding the treatment of chronic lymphocytic leukemia. CME information and select publications here .
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr James B Bussel from Weill Cornell School of Medicine in New York, New York, and Prof Nichola Cooper from Hammersmith Hospital Campus in London, United Kingdom, share expert perspectives on the diagnosis of and optimal management strategies for immune thrombocytopenia. CME information and select publications here .
Drs. Carla Casulo, Matthew Matasar, and Laurie Sehn discuss current and novel bispecific antibody treatments for relapsed/refractory follicular lymphoma, focusing on Mosunetuzumab, Epcoritimab, and Odronextamab. They compare their efficacy, safety profiles, and administration schedules, explore patient selection criteria, and the integration of these therapies into community practice. The discussion is enriched with real-world patient case studies and a look into future clinical trials, including considerations for infection risk and vaccination.
